MX2015008697A - Tratamiento contra la degeneración macular relacionada con la edad. - Google Patents

Tratamiento contra la degeneración macular relacionada con la edad.

Info

Publication number
MX2015008697A
MX2015008697A MX2015008697A MX2015008697A MX2015008697A MX 2015008697 A MX2015008697 A MX 2015008697A MX 2015008697 A MX2015008697 A MX 2015008697A MX 2015008697 A MX2015008697 A MX 2015008697A MX 2015008697 A MX2015008697 A MX 2015008697A
Authority
MX
Mexico
Prior art keywords
agent
rnai
macular degeneration
related macular
age
Prior art date
Application number
MX2015008697A
Other languages
English (en)
Inventor
Suhy David
Mao Tin
KAO Shih-Chu
Original Assignee
Benitec Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Biopharma Ltd filed Critical Benitec Biopharma Ltd
Publication of MX2015008697A publication Critical patent/MX2015008697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se dirige a un agente de interferencia de ARN (iARN) y el uso de ese agente de iARN para tratar la degeneración macular relacionada con la edad, así como a composiciones farmacéuticas que contienen los agentes de iARN de la invención. El agente de iARN es un agente de interferencia de ARN dirigido al ADN (iARNda) (que es una molécula de ARN), junto con una construcción o casete de expresión para expresar ese agente en una célula (incluyendo in vivo), para inhibir, prevenir o reducir la expresión de un gen asociado con la DME. Preferentemente, ese gen asociado con la DME es uno asociado con la DME húmeda.
MX2015008697A 2013-01-08 2014-01-08 Tratamiento contra la degeneración macular relacionada con la edad. MX2015008697A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750086P 2013-01-08 2013-01-08
PCT/AU2014/000007 WO2014107763A1 (en) 2013-01-08 2014-01-08 Age-related macular degeneration treatment

Publications (1)

Publication Number Publication Date
MX2015008697A true MX2015008697A (es) 2016-08-04

Family

ID=51166430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008697A MX2015008697A (es) 2013-01-08 2014-01-08 Tratamiento contra la degeneración macular relacionada con la edad.

Country Status (13)

Country Link
US (2) US10000753B2 (es)
EP (1) EP2943571A4 (es)
JP (1) JP2016507514A (es)
KR (1) KR20150103280A (es)
CN (1) CN105143450A (es)
AU (1) AU2014205036A1 (es)
CA (1) CA2897342A1 (es)
HK (1) HK1218656A1 (es)
IL (1) IL239836A0 (es)
MX (1) MX2015008697A (es)
RU (1) RU2015133252A (es)
SG (2) SG11201505272QA (es)
WO (1) WO2014107763A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
KR102344559B1 (ko) * 2013-12-12 2021-12-31 알닐람 파마슈티칼스 인코포레이티드 보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
DK3218386T3 (da) 2014-11-14 2021-06-07 Voyager Therapeutics Inc Modulatorisk polynukleotid
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US11839195B2 (en) 2016-01-21 2023-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Parthenocarpic tomato plants with loss of function mutation in an AGL6 gene and methods of producing same
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
MX2019007110A (es) * 2016-12-14 2019-12-05 Benitec Biopharma Ltd Reactivos para el tratamiento de la distrofia muscular oculofaringea (opmd) y uso de estos.
TW201827596A (zh) * 2016-12-23 2018-08-01 日商協和醱酵麒麟有限公司 抑制補體b因子之表現之核酸
WO2018141025A1 (en) * 2017-02-03 2018-08-09 Benitec Biopharma Limited Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
US11541072B2 (en) * 2017-06-27 2023-01-03 Massachusetts Eye And Ear Infirmary AAV-CRISPR/Cas9 genome editing of VEGFR2 for treating ocular diseases
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
BR112020005103A2 (pt) * 2017-09-15 2020-09-24 Commonwealth Scientific And Industrial Research Organisation molécula de rna, molécula de ácido ribonucleico (rna) quimérica, polinucleotídeo isolado e/ou exógeno, vetor, célula hospedeira, polinucleotídeo, organismo não humano, método, método para produzir um organismo não humano, extrato de uma célula hospedeira, composição, método para regular de modo decrescente o nível e/ou a atividade de uma molécula de rna-alvo em um organismo, método para controlar um organismo não humano, método para tratar uma doença em um indivíduo, molécula de rna, uso de uma molécula de rna e kit
JP7422069B2 (ja) 2017-09-19 2024-01-25 トロピック バイオサイエンシーズ ユーケー リミテッド 真核細胞において遺伝子発現をサイレンシングするための非コードｒｎａ分子の特異性の改変
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
WO2021050744A2 (en) * 2019-09-10 2021-03-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment methods for eye disorders
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
EP4263832A2 (en) 2020-12-18 2023-10-25 Yeda Research and Development Co. Ltd Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same
IL304068A (en) 2020-12-28 2023-08-01 1E Therapeutics Ltd DNA enzymes against p21 messenger RNA
EP4267741A2 (en) 2020-12-28 2023-11-01 1E Therapeutics, Ltd. P21 mrna target areas for silencing
GB202103256D0 (en) 2021-03-09 2021-04-21 Tropic Biosciences Uk Ltd Method for silencing genes
WO2022239001A1 (en) 2021-05-10 2022-11-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions for treating neurological conditions
CN118234861A (zh) * 2021-09-02 2024-06-21 赛伦斯治疗有限责任公司 用于抑制细胞中的补体因子b(cfb)表达的核酸
EP4415539A1 (en) 2021-10-14 2024-08-21 Weedout Ltd. Methods of weed control
KR20240095325A (ko) 2021-10-29 2024-06-25 알닐람 파마슈티칼스 인코포레이티드 보체 인자 b (cfb) irna 조성물 및 이의 사용 방법
WO2024149906A1 (en) 2023-01-13 2024-07-18 Laverock Therapeutics Limited Cell context-specific gene regulation using inhibitory rnas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
DK1725660T3 (da) * 2004-03-05 2011-08-29 Benitec Inc Ekspressionskassetter med multiple promotorer til samtidig afgivelse af RNAi-midler
CA2559161C (en) * 2004-03-12 2013-06-11 Alnylam Pharmaceuticals, Inc. Irna agents targeting vegf
US8282921B2 (en) * 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
US8076471B2 (en) * 2005-02-03 2011-12-13 Benitec, Inc. RNAi expression constructs
EP1874794A4 (en) * 2005-04-28 2009-07-29 Benitec Ltd MULTIPLE RNAI EXPRESSION CASSETTES FOR THE SIMULTANEOUS DELIVERY OF RNAI AGENTS ASSOCIATED WITH HETEROZYGOT EXPRESSION PATTERNS
AU2006315102A1 (en) * 2005-11-21 2007-05-24 Johnson & Johnson Research Pty Limited Multitargeting interfering RNAs having two active strands and methods for their design and use
GB0608838D0 (en) * 2006-05-04 2006-06-14 Novartis Ag Organic compounds
CN101674853B (zh) * 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
WO2008154482A2 (en) * 2007-06-08 2008-12-18 Sirnaomics, Inc. Sirna compositions and methods of use in treatment of ocular diseases
WO2009048932A2 (en) * 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
MX2011005851A (es) * 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
RU2013102545A (ru) * 2010-07-28 2014-09-10 Алкон Ресерч, Лтд. Связывающая vegfa си-рнк и способы лечения in vivo
US9220716B2 (en) * 2011-07-26 2015-12-29 Children's Medical Center Corporation Methods and compositions for the treatment of proliferative vascular disorders
EP2819703A4 (en) * 2012-02-29 2015-11-18 Benitec Biopharma Ltd TREATMENT OF PAIN

Also Published As

Publication number Publication date
SG11201505272QA (en) 2015-08-28
SG10201705518SA (en) 2017-08-30
KR20150103280A (ko) 2015-09-09
US20160145611A1 (en) 2016-05-26
CA2897342A1 (en) 2014-07-17
US10000753B2 (en) 2018-06-19
WO2014107763A1 (en) 2014-07-17
CN105143450A (zh) 2015-12-09
EP2943571A1 (en) 2015-11-18
IL239836A0 (en) 2015-08-31
AU2014205036A1 (en) 2015-07-30
HK1218656A1 (zh) 2017-03-03
US20180320180A1 (en) 2018-11-08
JP2016507514A (ja) 2016-03-10
EP2943571A4 (en) 2016-11-30
RU2015133252A (ru) 2017-02-10

Similar Documents

Publication Publication Date Title
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
ZA202110854B (en) Tmprss6 irna compositions and methods of use thereof
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
WO2014022739A3 (en) Modified rnai agents
MX2019003984A (es) Formulaciones de enzalutamida.
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
IN2015DN01156A (es)
MX2017016088A (es) Oligonucleotidos multi-conjugados definidos.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
SG10201811175WA (en) Method for treating cancer using a combination of chk1 and atr inhibitors
MX364486B (es) Derivados de piridazinona-amidas.
SG10201804472YA (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
MX2015007916A (es) Peri-carbinoles.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
PH12015501038A1 (en) Inhibitors of iap
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX362854B (es) Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.
PH12015500399A1 (en) Azaindolines
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.